Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Dahl TB, Aftab F, Prebensen C, Berdal JE, Ueland T, Barratt-Due A, Riise AMD, Ueland PM, Hov JR, Trøseid M, Aukrust P, Gregersen I, Myhre PL, Omland T, Halvorsen B(2025) Imidazole propionate is increased in severe COVID-19 and correlates with cardiac involvement J Infect, 106494(in press) DOI 10.1016/j.jinf.2025.106494, PubMed 40280497
Langslet G(2025) Adherence to lipid lowering therapy in primary prevention - Talk with the patient, again and again Eur J Prev Cardiol(in press) DOI 10.1093/eurjpc/zwaf260, PubMed 40279371
Lorentsen JLL, Brunborg C, Aasebø AT, Valeur J, Haavardsholm EA, Molberg Ø, Palm Ø, Lerang K(2025) Incidence and prevalence of Behçet's disease in Oslo Norway: a two-decade population-based analysis Rheumatology (Oxford)(in press) DOI 10.1093/rheumatology/keaf224, PubMed 40279276